Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.36 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111577 | 0.83 | NQO1 (0.47) | NQO1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL5345404 | 0.78 | CSNK2A2 (0.36) | CSNK2A2CSNK2BCSNK2A1CSNK2A3GPR35 | |
| SCHEMBL5343002 | 0.78 | CSNK2A2 (0.38) | CSNK2A2CSNK2BCSNK2A1ESR2ESR1 | |
| SCHEMBL5340548 | 0.78 | CA12 (0.49) | NQO1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL5338619 | 0.74 | PKLR (0.47) | ESR2ESR1MAOBMAOAALDH1A1 | |
| SCHEMBL5337618 | 0.70 | ESR2 (0.49) | ESR2ESR1MAOBMAOAALDH1A1 | |
| SCHEMBL5338654 | 0.70 | ESR2 (0.38) | NQO1ESR2 | |
| SCHEMBL5337992 | 0.70 | TTR (0.34) | NQO1 | |
| SCHEMBL5341857 | 0.69 | NQO1 (0.49) | NQO1CSNK2A2CSNK2BCSNK2A1ESR2 | |
| SCHEMBL5342546 | 0.69 | NQO1 (0.49) | NQO1CSNK2A2CSNK2BCSNK2A1CSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208518-B2 | Substituted furochromene compounds of antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-04-24 | — | — | US | claimed |
| US-20060148890-A1 | Substituted furochromene compounds of antiinflammatory action | PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-07-06 | — | — | US | claimed |
| EP-1648901-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2006-04-26 | — | — | EP | claimed |
| WO-2005010006-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-02-03 | — | — | WO | claimed |
| US-7208518-B2 | Substituted furochromene compounds of antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-04-24 | — | — | US | disclosed |
| US-7208518-B2 | Substituted furochromene compounds of antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-04-24 | — | — | US | disclosed |
| US-7208518-B2 | Substituted furochromene compounds of antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-04-24 | — | — | US | disclosed |
| US-20060148890-A1 | Substituted furochromene compounds of antiinflammatory action | PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-07-06 | — | — | US | disclosed |
| EP-1648901-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005010006-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148890-A1 | Substituted furochromene compounds of antiinflammatory action | LTC4S, CYP11B2, CYP11B1 | NQO1 91/4885CSNK2A2 1136/4885CSNK2B 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.